Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Human CCL19/MIP-3 beta Antibody, R&D Systems™

Mouse Monoclonal Antibody
Supplier: R&D Systems MAB3611
This item is not returnable.
View return policy
Description
CCL19/MIP-3 beta Monoclonal specifically detects CCL19/MIP-3 beta in Human samples. It is validated for Neutralization.Specifications
CCL19/MIP-3 beta | |
Monoclonal | |
Unconjugated | |
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 μm filtered solution in PBS. with No Preservative | |
beta chemokine exodus-3, Beta-chemokine exodus-3, CC chemokine ligand 19, C-C motif chemokine 19, chemokine (C-C motif) ligand 19, CKb11, EBI1-ligand chemokine, ELC, ELCMIP-3-beta, Epstein-Barr virus-induced molecule 1 ligand chemokine, exodus-3, Macrophage inflammatory protein 3 beta, macrophage inflammatory protein 3-beta, MGC34433, MIP3 beta, MIP-3 beta, MIP-3b, MIP3BCK beta-11, SCYA19EBI1 ligand chemokine, small inducible cytokine subfamily A (Cys-Cys), member 19, Small-inducible cytokine A19 | |
Mouse | |
Protein A or G purified from hybridoma culture supernatant | |
RUO | |
6363 | |
Reconstitute at 0.5 mg/mL in sterile PBS. | |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution. | |
IgG1 |
Neutralization | |
948918 | |
Neutralization 0.1-0.5 ug/mL | |
Q99731 | |
CCL19 | |
E. coli-derived recombinant human CCL19/MIP-3 beta Gly22-Ser98 Accession # Q99731 | |
100 μg | |
Primary | |
Detects human CCL19/MIP-3 beta in direct ELISAs. | |
Human | |
Purified |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
For Research Use Only
Spot an opportunity for improvement?Share a Content Correction